Evidence map›Paper›PMID 29367765›Full record

ArticleOncogene2018

Employing mesenchymal stem cells to support tumor-targeted delivery of extracellular vesicle (EV)-encapsulated microRNA-379.

K P O'Brien, S Khan, K E Gilligan, H Zafar, P Lalor, C Glynn, C O'Flatharta, H Ingoldsby, P Dockery, A De Bhulbh and 8 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 140 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
140citing papers in PubMed, 3 pooled it
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

140 citing papers in PubMed, 3 syntheses or guidelines pooled it, 207 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Potential biological roles of exosomal non-coding RNAs in breast cancer.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Review
  19. Review
  20. Exosomes and solid cancer therapy: where are we now?Medical oncology (Northwood, London, England) · 2025
    Review

80 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

K P O'BrienDiscipline of Surgery, Lambe Institute for Translational Research, School of Medicine, National University of Ireland Galway, Galway, Ireland.
S KhanDiscipline of Surgery, Lambe Institute for Translational Research, School of Medicine, National University of Ireland Galway, Galway, Ireland.
K E GilliganDiscipline of Surgery, Lambe Institute for Translational Research, School of Medicine, National University of Ireland Galway, Galway, Ireland.
H ZafarCardiovascular Research Centre Galway, School of Medicine, National University of Ireland Galway, Galway, Ireland.
P LalorDiscipline of Anatomy, School of Medicine, National University of Ireland Galway, Galway, Ireland.
C GlynnDiscipline of Surgery, Lambe Institute for Translational Research, School of Medicine, National University of Ireland Galway, Galway, Ireland.
C O'FlathartaRegenerative Medicine Institute (REMEDI), CURAM, National University of Ireland Galway, Galway, Ireland.
H IngoldsbyDivision of Anatomic Pathology, University Hospital Galway, Galway, Ireland.
P DockeryDiscipline of Anatomy, School of Medicine, National University of Ireland Galway, Galway, Ireland.
A De BhulbhDiscipline of Surgery, Lambe Institute for Translational Research, School of Medicine, National University of Ireland Galway, Galway, Ireland.
J R SchweberDiscipline of Surgery, Lambe Institute for Translational Research, School of Medicine, National University of Ireland Galway, Galway, Ireland.
K St JohnDiscipline of Surgery, Lambe Institute for Translational Research, School of Medicine, National University of Ireland Galway, Galway, Ireland.
M LeahyTissue Optics and Microcirculation Imaging Group, School of Physics, National University of Ireland Galway, Galway, Ireland.
J M MurphyRegenerative Medicine Institute (REMEDI), CURAM, National University of Ireland Galway, Galway, Ireland.
W M GallagherCancer Biology and Therapeutics Laboratory, UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland.
T O'BrienRegenerative Medicine Institute (REMEDI), CURAM, National University of Ireland Galway, Galway, Ireland.
M J KerinDiscipline of Surgery, Lambe Institute for Translational Research, School of Medicine, National University of Ireland Galway, Galway, Ireland.
R M DwyerDiscipline of Surgery, Lambe Institute for Translational Research, School of Medicine, National University of Ireland Galway, Galway, Ireland. roisin.dwyer@nuigalway.ie.
Ollscoil na Gaillimhe – University of Galway · IEUniversity College Dublin · IEUniversity Hospital Galway · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adult Mesenchymal Stem Cells (MSCs) have a well-established tumor-homing capacity, highlighting potential as tumor-targeted delivery vehicles. MSCs secrete extracellular vesicle (EV)-encapsulated microRNAs, which play a role in intercellular communication. The aim of this study was to characterize a potential tumor suppressor microRNA, miR-379, and engineer MSCs to secrete EVs enriched with miR-379 for in vivo therapy of breast cancer. miR-379 expression was significantly reduced in lymph node metastases compared to primary tumor tissue from the same patients. A significant reduction in the rate of tumor formation and growth in vivo was observed in T47D breast cancer cells stably expressing miR-379. In more aggressive HER2-amplified HCC-1954 cells, HCC-379 and HCC-NTC tumor growth rate in vivo was similar, but increased tumor necrosis was observed in HCC-379 tumors. In response to elevated miR-379, COX-2 mRNA and protein was also significantly reduced in vitro and in vivo. MSCs were successfully engineered to secrete EVs enriched with miR-379, with the majority found to be of the appropriate size and morphology of exosomal EVs. Administration of MSC-379 or MSC-NTC cells, or EVs derived from either cell population, resulted in no adverse effects in vivo. While MSC-379 cells did not impact tumor growth, systemic administration of cell-free EVs enriched with miR-379 was demonstrated to have a therapeutic effect. The data presented support miR-379 as a potent tumor suppressor in breast cancer, mediated in part through regulation of COX-2. Exploiting the tumor-homing capacity of MSCs while engineering the cells to secrete EVs enriched with miR-379 holds exciting potential as an innovative therapy for metastatic breast cancer.

Indexed as

Mesenchymal Stem Cell TransplantationAdult Stem CellsAnimalsBreast NeoplasmsCells, CulturedDrug CompoundingDrug Delivery SystemsExtracellular VesiclesFemaleGene Expression Regulation, NeoplasticGenetic TherapyHumansLymphatic MetastasisMesenchymal Stem CellsMiceMice, Inbred BALB CMicroRNAsMIRN379 microRNA, human

Identifiers

PMID29367765
OpenAlexW2793133729

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.